Description: Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
Home Page: www.acurapharm.com
616 N. North Court
Palatine,
IL
60067
United States
Phone:
847 705 7709
Officers
| Name | Title |
|---|---|
| Mr. Robert B. Jones | CEO, Pres & Director |
| Mr. Peter A. Clemens | Sr. VP, CFO & Sec. |
| Dr. Albert W. Brzeczko Ph.D. | VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. |
| Mr. Robert A. Seiser CPA, Ph.D. | VP, Treasurer & Corp. Controller |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.1071 |
| Price-to-Sales TTM: | 1.4496 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |